Paratek Pharmaceuticals, Inc. (PRTK)
(Delayed Data from NSDQ)
$5.36 USD
+0.04 (0.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $5.35 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[PRTK]
Reports for Purchase
Showing records 1 - 20 ( 187 total )
Industry: Medical - Biomedical and Genetics
2Q Recap; We Expect Paratek Shareholders to Approve Its Acquisition on September 18 Special Meeting; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
BARDA Contract Update Pulls Next Procurement Ahead to 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Paratek to Be Taken Private in Deal Worth Up to $462M; Downgrade to Neutral With $2.15 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
1Q Recap; Phase 2b NTM Data Expected in Mid-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
4Q Recap: Realizing that Paratek Is Still Suffering From ''Long Covid''; Reduce PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Milestone Payment of $36M Received From BARDA Project BioShield, as Anticipated; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Positive Pulmonary Anthrax Study Triggers Second BARDA Procurement of NUZYRA; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
3Q Recap; NUZYRA Community Expansion Continues; Next Round of BARDA Procurement Around YE22; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
KOL Webcast Highlights NUZYRA''s Significant Global Opportunity in NTM; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
2Q Recap; NUZYRA Demand Accelerates on Hospital Reopening and Sales Force Expansion; Momentum to Continue; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
FDA Grants Fast Track Designation For NUZYRA in NTM; Phase 2b Study Enrollment Continues; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
1Q22 Recap: Full-Year Commercial Revenue Guidance Upheld, Despite Q1 Blip From Omicron Variant; Moderate PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
4Q Recap; NUZYRA Marketing For Community Setting Ramps Up; Affirm Buy and Moderating PT to $22 on a Model Refresh
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Impressive Preclinical Results in MAC Lung Infections May Lead to Pan-NTM Development of NUZYRA
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Paratek Earns $6M Milestone Payment From Zai Lab From NMPA Approval of NUZYRA; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
3Q Recap; NUZYRA Sales Momentum Accelerates in 3Q, Bodes Well for 4Q and 2022; Modulate PT to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
NUZYRA Embarks Towards Significant Opportunity in NTM As Phase 2b Study Enrolled First Patient
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
IDWeek 2021: Poster Presentation Highlights Within Our Antibiotics Coverage Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
BARDA Contract Expanded, Now Valued at $304M; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E